Olivier de Beaumont
Chief Tech/Sci/R&D Officer presso Stallergenes Greer, Inc.
Profilo
Olivier de Beaumont is currently the Senior VP & Head-Global Clinical Development at Stallergenes Greer, Inc. He previously worked as the Senior Vice President-Global Medical Affairs at Stallergenes SA and as the Chief Medical Officer & Head-Regulatory Affairs at Valerio Therapeutics SA. Dr. de Beaumont holds an MBA degree from ESCP Europe.
Posizioni attive di Olivier de Beaumont
| Società | Posizione | Inizio |
|---|---|---|
Stallergenes Greer, Inc.
 Stallergenes Greer, Inc. Pharmaceuticals: MajorHealth Technology Part of Stallergenes Greer Ltd., Stallergenes Greer, Inc. specializes in the development and commercialization of allergy immunotherapy products for use in the diagnosis and treatment of allergies. The private company is based in Cambridge, MA. | Chief Tech/Sci/R&D Officer | 01/01/2005 |
Precedenti posizioni note di Olivier de Beaumont
| Società | Posizione | Fine |
|---|---|---|
| VALERIO THERAPEUTICS | Chief Tech/Sci/R&D Officer | 01/09/2022 |
| STALLERGENES | Corporate Officer/Principal | - |
Formazione di Olivier de Beaumont
| ESCP Europe | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| VALERIO THERAPEUTICS | Health Technology |
| Aziende private | 2 |
|---|---|
Stallergenes SA
 Stallergenes SA Pharmaceuticals: MajorHealth Technology Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France. | Health Technology |
Stallergenes Greer, Inc.
Stallergenes Greer, Inc. Pharmaceuticals: MajorHealth Technology Part of Stallergenes Greer Ltd., Stallergenes Greer, Inc. specializes in the development and commercialization of allergy immunotherapy products for use in the diagnosis and treatment of allergies. The private company is based in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Olivier de Beaumont
